ICCM Stock — Icecure Medical

Icecure Medical (ICCM)

Updated October 16, 2026.

ICCM is a Stock. Total return is -99.4% over the past 12.9 years, 542.2 points behind SPY at 442.8%.

IceCure Medical is a commercial-stage medical device company that develops and markets cryoablation systems and related disposables for treating tumors across multiple medical specialties, including oncology, urology, and dermatology. The company currently does not distribute to shareholders. This security appeals to investors seeking exposure to early-stage medical technology development with no expectation of near-term income.

ICCM performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.4% over the past 12.9 years, 542.2 points behind SPY at 442.8%. Over the past year its total return — price change plus distributions reinvested — is -95.7%. Its deepest 1-year drawdown was 96.0%.

ICCM key facts

Asset type

Stock

Asset class

Equity

Inception date

11/07/2013

Distribution frequency

None

Last close

$1.06 (as of 2026-10-16)

Market cap

$4,916,684

Average volume

101368.0

Beta

0.43

Payout ratio

0.0%

EPS

$-6.43

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ICCM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 96.0%.

Who may consider ICCM — and who may not

It is a weaker fit for investors who need monthly cash flow (ICCM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ICCM

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions